Pluristem's Company Overview

The attached information has been prepared by Pluristem Therapeutics, Inc. using its best efforts to realistically and factually present the information contained. However, subjective opinion, dependence upon factors outside Pluristem’s control and outside information sources unavoidably dictate that Pluristem cannot warrant the information contained to be exhaustive, complete or sufficient. In addition, many factors can affect Pluristem’s plans which could significantly alter the results intended by Pluristem, rendering Pluristem’s plans unattainable or substantially altered. Therefore, interested readers should conduct their own assessment and consult with their own professional advisors prior to making any investment or other decisions. Readers should also review the risk factors set out in Pluristem’s latest 10-KSB as filed on Edgar with the U.S. Securities and Exchange Commission (SEC).

 

Pluristem Therapeutics Inc. (NASDAQ: PSTI; DAX: PJT) is a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company’s first product in development, PLX-PAD, targets an annual $4 billion market and is intended to improve the quality of life of millions of people suffering from peripheral artery disease (PAD). The Company’s products in development also include PLX-IBD, which targets an annual $2 billion market and is intended to treat patients suffering from Inflammatory Bowel Disease (IBD), which includes Crohn’s disease and Ulcerative Colitis; PLX-MS, which targets an annual $5.4 billion market and is intended to treat Multiple Sclerosis; PLX-STROKE, which targets an annual $4 billion market and shows potential to become a new treatment for the functional recovery from an ischemic stroke; and PLX-BMT, which targets a $2 billion annual market and is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT);. Moreover, Pluristem believes its PLX cells are also potentially useful for other indications such as organ transplantation, orthopedic injuries and preventing radiation sickness.

Pluristem’s products are derived from adherent stromal cells (ASCs) obtained from the placenta, a non-controversial, non-embryonic, source of adult stem cells. The ASCs are then expanded in the Company’s proprietary PluriX™ 3D bioreactor. Pluristem's products are stored "ready to use" with no matching needed and have the potential to participate in the approximate $30 billion therapeutic and regenerative cellular market.

The Company’s proprietary PluriX™ 3D bioreactor imitates the natural microstructure of bone marrow and does not require supplemental growth factors, cytokines or other exogenous materials. Pluristem believes the resultant expanded cells, termed PLX (PLacental eXpanded) cells, are multi-potent and able to differentiate into a variety of cell types. Recent evidence also suggests their efficacy may be related to their secretion of cytokines or other potent immune modulators. Furthermore, PLX cells are immune-privileged and possess immunomodulatory properties, thus protecting the recipient from immunological reactions that often accompany transplantations.

 

Pluristem has offices in the USA with research and manufacturing facilities in Israel.

For further information, contact:

William R. Prather RPh, MD

Sr. VP Corporate Development

+1-303-883-4954

William.PratherMD@pluristem.com